<?xml version="1.0" encoding="UTF-8"?>
<p>The HMPV surface glycoproteins G and F have both been tested as vaccine antigens. When F and G genes were individually expressed in recombinant human parainfluenza virus-type 1 (hPIV-1) constructs and tested in hamsters, the F construct exhibited better immunogenicity [
 <xref rid="B63-pathogens-09-00109" ref-type="bibr">63</xref>]. In a separate study, when a soluble G protein was expressed (ectodomain without transmembrane domain or cytoplasmic tail), it did not elicit neutralizing antibodies or protection from challenge in cotton rats [
 <xref rid="B64-pathogens-09-00109" ref-type="bibr">64</xref>]. In contrast, HMPV F vaccines have been produced using a variety of different vector systems and have repeatedly generated protective immune responses in preclinical animal models [
 <xref rid="B59-pathogens-09-00109" ref-type="bibr">59</xref>,
 <xref rid="B60-pathogens-09-00109" ref-type="bibr">60</xref>,
 <xref rid="B61-pathogens-09-00109" ref-type="bibr">61</xref>].
</p>
